Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Alzinova AB interim report January – June 2020

The Board of Directors and the Chief Executive Officer of Alzinova AB hereby present the interim report for the second quarter 2020.Six months, January – June 2020 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -2 898 387 SEK (-2 737 617 SEK). · Earnings per share amounted to -0,38 SEK (-0,36 SEK) · Solidity amounted to 92,6% (95,5%). Three months, April – June 2020 · Net sales amounted to 0 SEK (0 SEK). · Result after financial items amounted to -1 123 481 SEK (-1 567 023 SEK). · Earnings per share amounted to -0.15 SEK (-0.21

Q1 Report - 30 June 2020

Flexion records strongest quarterly performance to date with total revenue up by 153%, gross margin up by 216% and adjusted EBITDA[‡] up by 103%. A new important milestone has been reached demonstrating a positive EBITDA for the first time during a quarter since the launch of its distribution services for Android games.April 2020 to June 2020 performance · Total revenue increased by 153% to GBP 4.8m (GBP 1.9m)* · Gross profit increased by 216% to GBP 0.7m (GBP 0.2m) · Adjusted EBITDA improved by 103% to GBP 0.02m  (GBP -0.5m) · Operating loss reduced by 81% to GBP -0.04m (GBP -

SciBase’s Nevisense product included in infant study at Mount Sinai Hospital

Stockholm, Sweden and New York, USA - August 26, 2020 - SciBase Holding AB  ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders, announced today that they will participate in a clinical study to run parallel to the ACTIVATE study (sponsored by the Immune Tolerance Network and the NIAID/NIH), which is being conducted by the Department of Pediatric Allergy at Mount Sinai Hospital in New York.The goal of the ACTIVATE study is to explore how differences in the gut microbiome of an infant affect its susceptibility to

Inhalation Sciences Sweden AB (publ) releases Interim Report Q2, January 1- June 30, 2020

(Stockholm, Sweden, August 26, 2020) During the second quarter 2020, Inhalation Sciences AB sold all its remaining shares in Ziccum AB for a total value of approximately SEK 21.2 million after selling expenses; it signed a global distribution agreement with TSE Systems GMBH, with an agreement to purchase at least three PreciseInhale® instruments, with associated modules, at an agreed minimum order value of SEK 3 million; it received a new contract research (Inhalation Research Services) assignment worth approx. SEK 0.8 million which will be performed using ISAB's leading in vitro dissolution

Interim report April-June 2020

Gothenburg, August 26, 2020 - Vicore Pharma Holding AB (publ) publishes the interim report for the second quarter 2020.Important events during the second quarter · In April, Vicore Pharma gained approval from the UK regulatory agency MHRA, to start the phase II study with VP01 on patients with COVID-19. The ATTRACT study is a randomized, double blind, placebo controlled study in approximately 100 COVID-19 patients with a moderately severe disease, treated with basic respiratory care, but not on mechanical ventilation. The study will investigate the efficacy on respiratory failure and

Hemsö to develop new elementary school in central Helsinki

Hemsö is developing a new elementary school for 700 pupils at the Arkadia 24 property in central Helsinki, Finland. The property will undergo extensive refurbishment and a 15-year rental agreement has been signed with the City of Helsinki. The Arkadia 28 property was acquired before the summer, and the Hanken School of Economics is relocating to the property.The properties are located in central Helsinki in a district famous for its public buildings, that include the Finnish Parliament House, Finlandia Hall and the National Museum of Finland. Hemsö has signed a rental agreement with the

I-Tech AB (publ) (ticker: ITECH) publish the interim report for the second quarter 2020

Summary of the period” Continued growth and positive development despite shipping headwinds ” Net turnover for the period amounted to kSEK 16,150 (12,582), corresponding to an increase in turnover of 28% (36%). Operating profit/loss amounted to kSEK 47 (-906). Net sales for the first half of the year amounted to kSEK 29 675 (18 752), corresponding to an increase in sales of 58% (43%).  Operating result amounted to kSEK -937 (-5 341). April to June 2020 ·I-Tech renewed and upgraded the regulatory status of Selektope® in Japan. ·At the Annual General Meeting,

Handelsbanken: Recovery in sight

There are signs of recovery after the historic drop in GDP and employment figures.“In the short term, GDP should rise sharply as more and more people return to work, but given the depth of the crisis, we expect the road to recovery to be rather long,” says Handelsbanken’s Chief Economist Christina Nyman. Despite the depth of the economic downturn, share prices and property prices have rebounded quickly – and in some cases they are higher now than before the crisis. The stock market rally can mainly be explained by the large stimulus measures, which have reduced the risk of bankruptcy

Karnov reports second quarter results 2020

Another solid quarterFINANCIAL HIGHLIGHTS SECOND QUARTER · Net sales up 3% to SEK 178 m (173), organic growth was 2%. · EBITA amounted to SEK 63 m (30) with EBITA margin of 35.5% (17.6%). · Adjusted EBITA increased by 5% to SEK 63 m (60) and adjusted EBITA margin was 35.5% (34.7%). · Net result amounted to SEK 27 m (-44). · Earnings per share after dilution amounted to SEK 0.27 (-0.45). · Adjusted operating cash flow improved by 171% to SEK 49 m (18). CEO flemming breinholt comments on the quarter: During the second quarter, Karnov Group continued to grow with

Interim Report January - June 2020

" Battery sensor advances” · Industrial feasibility study and extended grant funding. Outcome April to June · Net sales amounted to kSEK 335 (941). · Profit after net financial items amounted to kSEK -3 234 (-1 763). · Basic and diluted earnings per share: SEK -0,33 (-0,22). · Cash flow from operating activities and investing activities: kSEK 980 (-3 828). Significant events April – June · Insplorion project for multiplex NPS battery sensors is granted MSEK 1,9 from Vinnova. · Insplorion sells an Acoulyte instrument to Professor Moshe Herzberg at Ben-Gurion

Interim report January-June 2020

”Great margin development in the quarter” April-June 2020 · Sales in the quarter amounted to SEK 552.1 (532.3) million, an increase of 3.7 percent. Organic growth was 1.2 per cent after adjustment for a terminated unit in Svensk Markservice. · EBITA amounted to SEK 46.5 (26.2) million. An increase of 77.5 percent. · EBITA margin was 8.4 (4.9) percent. · Non-recurring items amounted to SEK 0.0 (8.7) million. · Cash flow from operating activities amounted to SEK 63.0 (45.5) million. · Net debt amounted to SEK 518.5 (652.9) million · Earnings per share amounted to SEK 0.

InDex Pharmaceuticals Holding AB (publ) interim report January – June 2020

Focus on phase III preparations“The commercial preparations have confirmed our belief in the potential of cobitolimod, where we estimate that the annual sales at a successful commercialisation can reach more than USD 1 billion,” says Peter Zerhouni, CEO of InDex Pharmaceuticals.  Period April – June 2020 · Net sales amounted to SEK 0.0 (0.0) million · Operating loss amounted to SEK –15.6 (–17.7) million · Result after tax amounted to SEK –15.6 (–17.7) million, corresponding to SEK –0.17 per share (–0.26) before and after dilution · Cash flow from operating activities

INTERIM REPORT Q2 2020

Summary Financial overview April 1 – June 30, 2020 · Net sales amounted to SEK 0.0 M (0.0) · Loss for the period was SEK 401.0 M (loss: 171.9) · Loss per share, before and after dilution, was SEK 6.79 (loss: 3.52) · On June 30 cash and cash equivalents amounted to SEK 937.8 M (626.8) Significant events during the period April 1 – June 30, 2020 · Marty J Duvall was appointed CEO from July 1, and Jakob Lindberg assumed the role as · Chief Scientific Officer · NDA for accelerated approval of melflufen in the U.S was submitted · A laboratory for preclinical

Stora Enso to build a pilot plant for bio-based packaging foam

STORA ENSO OYJ PRESS RELEASE 26 August 2020 at 9:00 EESTStora Enso will build a pilot facility for producing Cellulose foam by Stora Enso, a lightweight, fiber-based foam material for protective packaging and cushioning. Bio-based foams are renewable and recyclable and can be used in packaging, for example, to replace oil-based polymer foams which are widely used today. The pilot plant will be located at Stora Enso’s Fors Mill in Sweden.Cellulose foam by Stora Enso is a sustainable packaging material and it further increases Stora Enso’s opportunities to replace fossil-based materials

INTERNATIONELLA ENGELSKA SKOLAN YEAR-END REPORT 1 JULY–30 JUNE 2019/2020

Fourth quarter (April–June) · Operating income increased 7.1% to MSEK 810.2 (756.5), of which organic growth amounted to 3.5% · The number of students in the Swedish schools at the end of the quarter was 26,725 (25,536) · The number of registrations in the queue in Sweden at the end of the quarter was about 204,900 (191,700) · EBIT amounted to MSEK 89.3 (71.0). Excl. IFRS 16, EBIT amounted to MSEK 77.4 (71.0) · EBIT adjusted for non-recurring items of MSEK –1.0 (–) related to the Spanish acquisitions and excl. IFRS 16 amounted to MSEK 78.4 (71.0). · The adjusted EBIT

SCA intends to invest in pulp production and initiates consultations to discontinue publication paper

SCA intends to invest SEK 1,45bn in the production of chemically pre-treated thermo-mechanical pulp (CTMP) at the Ortviken paper mill in Sundsvall. In parallel, SCA is initiating consultations with trade unions and employee representatives to discontinue the production of publication paper at the mill.SCA intends to invest to achieve an annual production volume of 300,000 tonnes of CTMP pulp at Ortviken, using the existing infrastructure. The investment  is expected to give a positive EBITDA-effect of approximately SEK 0.3bn per annum. Expected start of production in the new mill is the

Licensing agreement in India enables advanced cancer treatment with Elekta Unity

GURGAON, India, August 26, 2020 – Elekta (EKTA-B.ST) announced today that it has entered a service agreement with Healthcare Global Enterprises Ltd (HCG), India’s largest provider of cancer care. According to the agreement, Elekta will install multiple Versa HD™ and Elekta Synergy[®] linear accelerators (linacs), as well as an Elekta Unity MR-Linac, a radiation therapy system that allows doctors to see a tumor’s movements and its exact position during the delivery of therapeutic radiation. Also included in the agreement are Elekta’s MOSAIQ[®] Oncology Information System (OIS) and its Monaco[

Interim report January 1 - June 30, 2020

“In the second quarter, net sales declined 14 percent due to lower license sales as a result of COVID-19. Operating loss totaled SEK -11 M (29), however adjusted for currency conversion effects the operating profit would have been SEK 16 M (25). Cash flow was strong and totaled SEK 66 M (4)”, Johan Löf, CEO of RaySearchSECOND QUARTER (APRIL-JUNE 2020) · Order intake SEK 177.1 M (370.6) · Net sales SEK 163.8 M (189.7) · Operating loss SEK -10.9 M (28.8) · Loss after tax SEK -9.2 M (21.8) andloss per share before/after dilution SEK -0.27 (earnings 0.64) · Cash flow SEK 65.9

Adelis portfolio company SSI Diagnostica acquires US-based CTK Biotech, creating global rapid diagnostics powerhouse

Since being acquired by Adelis Equity Partners Fund I AB (Adelis) in 2016, SSI Diagnostica has seen strong progress in its In Vitro Diagnostics (IVD) business, particularly internationally. To further accelerate its growth, SSI Diagnostica is acquiring the US-based IVD company CTK Biotech. The combination of the companies will create a global powerhouse within respiratory and tropical disease rapid diagnostics. The joint company will have very strong manufacturing and R&D capabilities as exemplified by its response to the Covid 19 health crisis. In connection with the transaction a CEO change

Interim report, May–July 2020/21

Showing resilience The world is still impacted by the Covid-19 pandemic, our industry included. But Elekta’s solid performance with positive order growth and increased profitability during the first quarter is a clear sign of our resilience and the strong underlying demand for our products. Elekta has a vital role to play for precision radiation medicine solutions – now in this time of transition and in a future situation when life will be normalized in our markets. We act forcefully to mitigate the short-term effects of the pandemic and continue to invest in innovation for long-term

Second quarter report 2020

Continued strong operating performance26 August 2020 · Net sales decreased by 1 percent to MSEK 2,448 (2,472) in the second quarter 2020. Net sales increased in Ireland and Finland but decreased in Sweden, Denmark and Norway. · Adjusted operating income[1)] increased to MSEK 122 (115), corresponding to a margin of 5.0 (4.6) per­cent. · Income for the period increased to MSEK 73 (50). Earnings per share increased to SEK 1.19 (0.78). The change compared to previous year was positively impacted by higher operating income despite non-comparables related to Covid-19 pandemic, as well

Interim report, January - June 2020

Strong quarter despite the current market situationApril - June 2020• Net sales increased by 31% Y-O-Y adjusted for exchange rate fluctuations • Consolidated net sales ended at 39,061 (SEK 000s) • EBITDA totaled to 5,326 (SEK 000s) (13,1% margin) • Operating profit, EBIT, was 3,297 (SEK 000s) • Profit after tax was 260 (SEK 000s) • Earnings per share SEK 0.004   January - June 2020• Net sales increased by 33% Y-O-Y adjusted for exchange rate fluctuations • Consolidated net sales ended at 81,049 (SEK 000s) • EBITDA totaled 5,994 (SEK 000s) (7,2% margin) •

Webstep ASA: Second quarter results 2020

Oslo 26 August 2020: Webstep ASA reports revenue growth and increased margin for the second quarter 2020. Revenues for the second quarter increased to NOK 172.4 million (NOK 162.0 million), EBIT increased to NOK 23.2 million (NOK 19.6 million), and the EBIT-margin increased to 13.5 per cent (12.1 per cent).Revenues were positively affected by increased headcount and higher hourly rates, but the growth has been partly offset by decreased revenues from subcontractors. The COVID-19 outbreak affected revenues negatively by approximately NOK 10 million in the second quarter, mainly due to the

Strong quarter and continued growth

Multiconsult had a strong second quarter 2020 with an EBIT at NOK 102.5 million. For the first half of 2020 the EBIT was NOK 219.9 million, an improvement of 187.3% y-o-y. The EBIT margin in the second quarter was 10.8%, and 11.3% in the first half 2020. Net operating revenues in the second quarter increased by 9.8% y-o-y to NOK 951.7 million, other operating expenses were reduced by 13.1% to 108.4 million, and the billing ratio was improved to 73.8%. The nextLEVEL improvement programme is on track, partly reflected in a reduction in other operating expenses of 12.7% y-o-y to NOK 218.4

There are no items matching the current filter
There are no more items matching the current filter
Back to top